Literature DB >> 18809298

Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis.

Cheryl M Corcoran1, David Kimhy, Arielle Stanford, Shamir Khan, Julie Walsh, Judy Thompson, Scott Schobel, Jill Harkavy-Friedman, Ray Goetz, Tiziano Colibazzi, Victoria Cressman, Dolores Malaspina.   

Abstract

BACKGROUND: Cannabis use is reported to increase the risk for psychosis, but no prospective study has longitudinally examined drug use and symptoms concurrently in clinical high risk cases.
METHOD: We prospectively followed for up to 2 years 32 cases who met research criteria for prodromal psychosis to examine the relationship between substance use and clinical measures.
RESULTS: Cases with a baseline history of cannabis use (41%) were older, but did not differ in clinical measures. Longitudinal assessments showed these cases had significantly more perceptual disturbances and worse functioning during epochs of increased cannabis use that were unexplained by concurrent use of other drugs or medications.
CONCLUSIONS: These data demonstrate that cannabis use may be a risk factor for the exacerbation of subthreshold psychotic symptoms, specifically perceptual disturbances, in high risk cases.

Entities:  

Mesh:

Year:  2008        PMID: 18809298      PMCID: PMC2613445          DOI: 10.1016/j.schres.2008.08.008

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  34 in total

1.  Treatment histories of patients with a syndrome putatively prodromal to schizophrenia.

Authors:  Adrian Preda; Tandy J Miller; Joanna Lifshey Rosen; Lubna Somjee; Thomas H McGlashan; Scott W Woods
Journal:  Psychiatr Serv       Date:  2002-03       Impact factor: 3.084

2.  Genetic liability, illicit drug use, life stress and psychotic symptoms: preliminary findings from the Edinburgh study of people at high risk for schizophrenia.

Authors:  P Miller; S M Lawrie; A Hodges; R Clafferty; R Cosway; E C Johnstone
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2001-07       Impact factor: 4.328

3.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study.

Authors:  Louise Arseneault; Mary Cannon; Richie Poulton; Robin Murray; Avshalom Caspi; Terrie E Moffitt
Journal:  BMJ       Date:  2002-11-23

Review 4.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

5.  Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group.

Authors:  Lisa J Phillips; Christina Curry; Alison R Yung; Hok Pan Yuen; Steven Adlard; Patrick D McGorry
Journal:  Aust N Z J Psychiatry       Date:  2002-12       Impact factor: 5.744

6.  Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study.

Authors:  L Hides; S Dawe; D J Kavanagh; R McD Young
Journal:  Br J Psychiatry       Date:  2006-08       Impact factor: 9.319

7.  Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder.

Authors:  S Sevy; D G Robinson; S Holloway; J M Alvir; M G Woerner; R Bilder; R Goldman; J Lieberman; J Kane
Journal:  Acta Psychiatr Scand       Date:  2001-11       Impact factor: 6.392

8.  Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.

Authors:  M Hambrecht; H Häfner
Journal:  Aust N Z J Psychiatry       Date:  2000-06       Impact factor: 5.744

9.  Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome.

Authors:  Joanna L Rosen; Tandy J Miller; Jennifer T D'Andrea; Thomas H McGlashan; Scott W Woods
Journal:  Schizophr Res       Date:  2006-05-02       Impact factor: 4.939

10.  Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study.

Authors:  H Verdoux; C Gindre; F Sorbara; M Tournier; J D Swendsen
Journal:  Psychol Med       Date:  2003-01       Impact factor: 7.723

View more
  32 in total

1.  Early prodromal symptoms can predict future psychosis in familial high-risk youth.

Authors:  Neeraj Tandon; Debra Montrose; Jai Shah; R P Rajarethinam; Vaibhav A Diwadkar; Matcheri S Keshavan
Journal:  J Psychiatr Res       Date:  2011-11-04       Impact factor: 4.791

2.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

3.  Effects of Δ-THC on Working Memory: Implications for Schizophrenia?

Authors:  Nehal P Vadhan; Mark R Serper; Margaret Haney
Journal:  Prim psychiatry       Date:  2009-01-01

4.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

5.  Acute effects of smoked marijuana in marijuana smokers at clinical high-risk for psychosis: A preliminary study.

Authors:  Nehal P Vadhan; Cheryl M Corcoran; Gill Bedi; John G Keilp; Margaret Haney
Journal:  Psychiatry Res       Date:  2017-08-01       Impact factor: 3.222

6.  Cannabis and Psychosis: What Can Daily Diaries Tell Us About Who is Vulnerable?

Authors:  David Kimhy; Kelly Durbin; Cheryl M Corcoran
Journal:  Prim psychiatry       Date:  2009

Review 7.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

8.  Telepsychotherapy with Youth at Clinical High Risk for Psychosis: Clinical Issues and Best Practices during the COVID-19 Pandemic.

Authors:  Joseph S DeLuca; Nicole D Andorko; Doha Chibani; Samantha Y Jay; Pamela J Rakhshan Rouhakhtar; Emily Petti; Mallory J Klaunig; Elizabeth C Thompson; Zachary B Millman; Kathleen M Connors; LeeAnn Akouri-Shan; John Fitzgerald; Samantha L Redman; Caroline Roemer; Miranda A Bridgwater; Jordan E DeVylder; Cheryl A King; Steven C Pitts; Shauna P Reinblatt; Heidi J Wehring; Kristin L Bussell; Natalee Solomon; Sarah M Edwards; Gloria M Reeves; Robert W Buchanan; Jason Schiffman
Journal:  J Psychother Integr       Date:  2020-06

9.  A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development.

Authors:  Chaturaka Rodrigo; Srina Welgama; Alwis Gunawardana; Chinthaka Maithripala; Gamini Jayananda; Senaka Rajapakse
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-07-08

10.  Cannabis use and cognition in schizophrenia.

Authors:  Else-Marie Løberg; Kenneth Hugdahl
Journal:  Front Hum Neurosci       Date:  2009-11-24       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.